Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
CHINA SHENGHUO PHARMACEUTICAL Aktie jetzt für 0€ handeln |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
DIGICANN VENTURES | 0,004 | 0,00 % | CSE Bulletin: Halted for Fundamental Change - Digicann Ventures Inc. (DCNN) | le 30 septembre/September 2024
Trading in the shares of Digicann Ventures Inc. will remain halted pending receipt and review of acceptable documentation regarding the Fundamental Change pursuant... ► Artikel lesen | |
WPD PHARMACEUTICALS | 0,002 | -33,33 % | CSE Bulletin: Consolidation - WPD Pharmaceuticals Inc. (WBIO) | le 23 décembre/December 2024
WPD Pharmaceuticals Inc. has announced a consolidation of its issued and outstanding common shares on the basis of one (1) post-consolidated common share for every twenty-five... ► Artikel lesen | |
IONIS PHARMACEUTICALS | 36,350 | 0,00 % | IONIS PHARMACEUTICALS INC - 8-K, Current Report | ||
SINOPHARM | 2,662 | +0,87 % | Aktie der Sinopharm Group kann Vortagsniveau nicht halten (2,451 €) | Das Wertpapier der Sinopharm Group notiert heute ein wenig leichter. Die Aktie notiert zur Stunde bei 2,45 Euro. Die Sinopharm Group-Aktie verzeichnet derzeit einen Kursverlust von 1,11 Prozent. Sie... ► Artikel lesen | |
INDIVA | 0,016 | 0,00 % | SNDL Inc.: SNDL Emerges as Canada's Leading Producer of Edibles with Indiva Acquisition | CALGARY, AB, Nov. 4, 2024 /CNW/ - SNDL Inc. (Nasdaq: SNDL) ("SNDL" or the "Company") announced today that, in the context of Indiva Limited's ("Indiva" and together... ► Artikel lesen | |
CSPC PHARMA | 0,580 | -1,02 % | CSPC PHARMA (01093): VOLUNTARY ANNOUNCEMENT - SYH2062 INJECTION (SIRNA DRUG) OBTAINS CLINICAL TRIAL APPROVAL | ||
ORAMED PHARMACEUTICALS | 2,360 | -0,84 % | Oramed Pharmaceuticals Inc.: Oramed Pharmaceuticals Announces Restructuring of Scilex Holding Company Debt | NEW YORK, Oct. 7, 2024 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) ("Oramed"), a clinical-stage pharmaceutical company focused on the development of oral drug delivery... ► Artikel lesen | |
ADASTRA | 0,204 | +36,91 % | Adastra Holdings Ltd.: Adastra Holdings Announces Annual General Meeting | Langley, British Columbia--(Newsfile Corp. - December 10, 2024) - Adastra Holdings Ltd. (CSE: XTRX) (FSE: D2E0) ("Adastra" or the "Company"), a leader in cannabis processing and production, is pleased... ► Artikel lesen | |
ACADIA PHARMACEUTICALS | 17,390 | +1,87 % | Acadia Pharmaceuticals Reports Third Quarter 2024 Financial Results and Operating Overview | SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced its financial results for the third quarter ended September 30, 2024.
"The success of Acadia's two growing... ► Artikel lesen | |
SELLAS LIFE SCIENCES | 1,010 | 0,00 % | SELLAS Life Sciences Group, Inc.: SELLAS Life Sciences Triggers Interim Analysis in Phase 3 REGAL Trial of GPS in Acute Myeloid Leukemia | - Study Reaches Pre-Specified Threshold of 60 Events (Deaths) Initiating the Interim Analysis - - REGAL Independent Data Monitoring Committee to Perform Interim Analysis in January 2025 - - Company... ► Artikel lesen | |
MADRIGAL PHARMACEUTICALS | 313,98 | 0,00 % | Arrowhead Pharma und Madrigal gehen steil: Zwischen Adipositas- und Übernahmefantasie | Die Biotechnologie-Branche bietet viele spannende Storys. Einen aussichtsreichen Aktienkorb mit 14 verschiedenen Titeln bildet der Biotech Supertrends Index ab. Zuletzt sorgten im Index vor allem die... ► Artikel lesen | |
CATALYST PHARMACEUTICALS | 21,930 | +1,43 % | Catalyst Pharmaceuticals, Inc.: Catalyst Pharmaceuticals Announces Sub-Licensee DyDo Pharma Received Approval to Commercialize FIRDAPSE in Japan | CORAL GABLES, Fla., Sept. 24, 2024 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing... ► Artikel lesen | |
MOLECULE HOLDINGS | 0,001 | 0,00 % | Molecule Holdings Inc: Molecule amends, settles, converts debentures | ||
NUMINUS WELLNESS | 0,024 | +10,91 % | Numinus Wellness Inc.: Numinus Wellness Comments on FDA Decision on New Drug Application for MDMA-Assisted Therapy for PTSD | VANCOUVER, BC, Aug. 12, 2024 /PRNewswire/ - Numinus Wellness Inc. ("Numinus" or the "Company") (TSX: NUMI) (OTCQX: NUMIF), a leader in mental health care specializing in innovative and evidence-based... ► Artikel lesen | |
OPUS GENETICS | 1,070 | 0,00 % | Opus Genetics, Inc.: Opus Genetics Receives FDA Agreement Under Special Protocol Assessment for Phase 3 Trial of APX3330 in Diabetic Retinopathy | Agreement Reached on Primary Endpoint and Phase 3 Trial Design Oral APX3330 is a Late-Stage Clinical Asset Available for Partnering FARMINGTON HILLS, Mich., Dec. 19, 2024 (GLOBE NEWSWIRE) --... ► Artikel lesen |